An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension
2022-06-29
عنوان الدراسة
An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension
داعم الدراسة
Biogen
دواء الدراسة
Interferon beta-1a
رقم بروتوكول الدراسة
105MS306
حالة الدراسة
Ongoing
موقع الدراسة
KFSH&RC-J
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。